Clinical Trials Browser

Phase 2 × Myelodysplastic Syndromes × eprenetapopt × Clear all

NCT03931291 2025-03-17

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Phase 2 Completed

33 enrolled 7 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute